RxDoctor Payments DataLook up a doctor →

Demetris Green, MD

General Practice · Houston, TXNPI 1699973420

Payments from drug & device makers

$25,758in general payments, 2019–2025

Across 832 payments — averaging $30.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$3K
  • Lilly USA, LLC$2K
  • GSK$2K
  • Bayer$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $13K from 36 others

What the payments were for

  • Consulting fees$9003%
  • Travel & lodging$70%
  • Food & beverage$24,79796%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,758 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$11,421
Medicare patients
27
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi22$80,947
OzempicSemaglutide43$48,693
KerendiaFinerenone16$25,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,064
Synjardy XrEmpagliflozin/Metformin Hcl18$15,187
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$13,198
JanuviaSitagliptin Phosphate15$12,343
JanumetSitagliptin Phos/Metformin Hcl13$12,057
EliquisApixaban17$11,392
BenicarOlmesartan Medoxomil12$4,744
Rosuvastatin Calcium119$3,368
Gabapentin108$3,278
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide97$2,457
Atorvastatin Calcium220$2,366
Buprenorphine Hcl12$1,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$112$80,94722 claims
Novo NordiskOzempic$3,291$48,69343 claims
BayerKerendia$1,613$25,88616 claims
MerckJanuvia, Janumet$191$24,40028 claims
GSKTrelegy Ellipta$1,642$16,06421 claims
Boehringer IngelheimSynjardy Xr$1,157$15,18718 claims
PfizerEliquis$533$11,39217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →